DOCK8 deficiency

Annals of the New York Academy of Sciences

Volumn 1246, Issue 1, 2011, Pages 26-33

  Su, Helen C ^a   Jing, Huie ^a   Zhang, Qian ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Combined immunodeficiency; DOCK8; Hyper IgE syndrome; Lymphopenia

Indexed keywords

BETA ACTIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMMUNOGLOBULIN E; PROTEIN DOCK2; PROTEIN DOCK8; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; AUTOIMMUNITY; AUTOSOMAL RECESSIVE DISORDER; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER SUSCEPTIBILITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMBINED IMMUNODEFICIENCY; DOCK8 DEFICIENCY; DOCK8 GENE; GENE; GENE MUTATION; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION SENSITIVITY; MYCOSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

EID: 84855317080     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06295.x     Document Type: Review

References (51)

1. Zhang, Q. et al. 2009. Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 361: 2046-2055.
2. Engelhardt, K.R. et al. 2009. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J. Allergy Clin. Immunol. 124: 1289-1302.e1284.
3. Ruusala, A. & P. Aspenstrom. 2004. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett. 572: 159-166.
4. Cote, J.F. & K. Vuori. 2002. Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. J. Cell. Sci. 115: 4901-4913.
5. Tybulewicz, V.L. & R.B. Henderson. 2009. Rho family GTPases and their regulators in lymphocytes. Nat. Rev. Immunol. 9: 630-644.
6. Freeman, A.F. & S.M. Holland. 2010. Clinical manifestations of hyper IgE syndromes. Dis. Markers 29: 123-130.
7. Minegishi, Y. et al. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448: 1058-1062.
8. Holland, S.M. et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357: 1608-1619.
9. Woellner, C. et al. 2010. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J. Allergy Clin. Immunol. 125: 424-432.
10. Renner, E.D. et al. 2004. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J. Pediatr. 144: 93-99.
11. Minegishi, Y. et al. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25: 745-755.
12. Woellner, C. et al. 2007. The hyper IgE syndrome and mutations in TYK2. Immunity 26: 535; author reply 536.
13. Grant, A.V. et al. 2011. Accounting for genetic heterogeneity in homozygosity mapping: application to Mendelian susceptibility to mycobacterial disease. J. Med. Genet. 48: 567-571.
14. Ozcan, E., L.D. Notarangelo & R.S. Geha. 2008. Primary immune deficiencies with aberrant IgE production. J. Allergy Clin. Immunol. 122: 1054-1062; quiz 1063-1054.
15. Lambe, T. et al. 2011. DOCK8 is essential for T-cell survival and the maintenance of CD8(+) T-cell memory. Eur. J. Immunol. [Epub ahead of print] doi:.
16. Randall, K.L. et al. 2011. DOCK8 deficiency cripples CD8 T cells in humans and mice. J. Exp. Med. 208: 2305-2320.
17. Dasouki, M. et al. 2011. Deficient T Cell Receptor Excision Circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection by newborn screening. Clin. Immunol. 141: 128-132.
18. Randall, K.l. et al. 2009. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat. Immunol. 10: 1283-1291.
19. Fukui, Y. et al. 2001. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412: 826-831.
20. Nombela-Arrieta, C. et al. 2004. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity 21: 429-441.
21. Nombela-Arrieta, C. et al. 2007. A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. J. Exp. Med. 204: 497-510.
22. Sanui, T. et al. 2003. DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-theta and LFA-1, in T cells. Immunity 19: 119-129.
23. Tanaka, Y. et al. 2007. T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2. Nat. Immunol. 8: 1067-1075.
24. Barlogis, V. et al. 2011. Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. J. Allergy Clin. Immunol. 128: 420-422.e2.
25. Gotoh, K. et al. 2010. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J. Exp. Med. 207: 721-730.
26. Blundell, M.P. et al. 2010. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Dis. Markers 29: 157-175.
27. Bachelerie, F. 2010. CXCL12/CXCR4-axis dysfunctions: markers of the rare immunodeficiency disorder WHIM syndrome. Dis. Markers 29: 189-198.
28. Al Khatib, S. et al. 2009. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J. Allergy Clin. Immunol. 124: 342-348, 348.e341-345.
29. Milner, J.D. et al. 2008. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452: 773-776.
30. Schimke, L.F. et al. 2010. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J. Allergy Clin. Immunol. 126: 611-617.e611.
31. Zhang, Q. et al. 2010. Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome. Dis. Markers 29: 131-139.
32. Puel, A. et al. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332: 65-68.
33. Ma, C.S. et al. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205: 1551-1557.
34. de Beaucoudrey, L. et al. 2008. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 205: 1543-1550.
35. Renner, E.D. et al. 2008. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 122: 181-187.
36. Minegishi, Y. et al. 2009. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J. Exp. Med. 206: 1291-1301.
37. Yang, X.P. et al. 2011. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12: 247-254.
38. Bittner, T.C. et al. 2010. Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin. Padiatr. 222: 351-355.
39. Su, H.C. 2010. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr. Opin. Allergy Clin. Immunol. 10: 515-520.
40. Lei, J.Y. et al. 2000. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am. J. Dermatopathol. 22: 524-529.
41. Sato, M. et al. 2005. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer 44: 405-414.
42. Takahashi, K. et al. 2006. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int. J. Oncol. 28: 321-328.
43. Heidenblad, M. et al. 2004. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 64: 3052-3059.
44. Kang, J.U. et al. 2010. Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int. J. Oncol. 37: 327-335.
45. Takada, H. et al. 2006. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 25: 6554-6562.
46. Idbaih, A. et al. 2008. Genomic changes in progression of low-grade gliomas. J. Neurooncol. 90: 133-140.
47. Saelee, P. et al. 2009. Novel PNLIPRP3 and DOCK8 gene expression and prognostic implications of DNA loss on chromosome 10q25.3 in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 10: 501-506.
48. Yavuz, H. & R. Chee. 2010. A review on the vascular features of the hyperimmunoglobulin E syndrome. Clin. Exp. Immunol. 159: 238-244.
49. Freeman, A.F. et al. 2011. Coronary artery abnormalities in hyper-IgE syndrome. J. Clin. Immunol. 31: 338-345.
50. Gatz, S.A. et al. 2011. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant 46: 552-556.
51. McDonald, D.R. et al. 2010. Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. J. Allergy Clin. Immunol. 126: 1304-1305.e3.